SAGA Diagnostics

Rwanda
Byumba, Northern Province, Rwanda, 223 81

Company profile

SAGA Diagnostics company profile

SAGA Diagnostics AB is a personalized cancer diagnostics and disease monitoring company focused on molecular genetic analyses of a powerful cancer biomarker: circulating tumor DNA (ctDNA). The company was founded in 2016 as a spin-out from a highly successful research group at Lund University, with a mission to improve precision cancer medicine, provide more accurate treatment monitoring, and improve patient survival using minimally-invasive liquid biopsy cancer testing services and kits. The SAGA team consists of renowned scientists, highly qualified staff and an experienced management team who work together to launch SAGA’s ultrasensitive services and products as part of the ongoing revolution in cancer research, drug development, and clinical diagnostics. SAGA’s proprietary tests can help patients, oncologists, and drug developers detect actionable mutations, stratify patient groups, and monitor treatment response, residual disease, and disease recurrence at an unprecedented sensitivity.

Business identity

Contact email
[email protected]
Phone number
+46 (0)733 01 7242
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2016-01-01, Year

Headquarters

Postal code
223 81
Country code
RW
Continent
Africa

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
6
Total equity funding
$17.9M
Last funding
Series A / $12.4M / 2021-06-29
Last equity funding
Series A / $12.4M
Investors
11
Lead investors
5
Founders
2
Articles
27

Founders and investors

Founders

Anthony GeorgeLao Saal

Lead investors

EISMEAHadean VenturesScietySegulah Medical AccelerationSmiLe Incubator

Investors

EISMEAHadean VenturesLU InnovationScietySegulah Medical Acceleration